



Save the Date | DSBS Afternoon meeting

Health Technology Assessment

28th February 2024

Novo Nordisk A/S

Building VTD, Knud Højgaardsvej 1, Søborg

Meeting Objective:

Health Technology Assessment (HTA) has been around for a long time, but chances are that it hasn't been a very significant part of your workday. This could change in coming years. From January 2025, in less than a year from now, Europe will start to implement a joint system for HTA, not unlike that of EMA regulatory assessment. Manufacturers must submit a joint EU HTA evidence dossier at the same time while EMA regulatory review is ongoing. This means more work for statisticians, but also new opportunities to contribute our expertise.

Navigating this new reality of EU HTA starts with understanding what HTA is all about, and what the role of statistics and statisticians is and could be. Join us for an afternoon in the name of HTA to hear perspectives from different stakeholders in the process and an opportunity to network with your DSBS colleagues.

Speakers:

- Anderst Gorst-Rasmussen (Director Biostatistics HTA, Novo Nordisk) (Meeting Chair)
- Christian Dehlendorff (Chief Consultant, Danish Medicines Council)
- Xin Ying Lee (HEOR Senior Specialist, Lundbeck A/S)
- Simon Bertram Reuter (Associate Payer Evidence Generation Director, Novo Nordisk)

Time 28th February:

15:15-17:00

(Arrival possible from 14:15)

Venue Novo Nordisk A/S

Knud Højgaardsvej 1

2860 Søborg

Registration

Attendance is free.

Registration is needed and will open in mid-February